Pharmaceuticals

IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innoven...

2022-06-02 20:08 3060

ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic

- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms - Build vertically integrated internal capabilities for more efficient drug development WOODINVILLE, Wash. and SUZHOU, China...

2022-06-02 20:00 2351

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy

Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, Australia, June 2, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disea...

2022-06-02 20:00 2261

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

SUZHOU, China, June 2, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for...

2022-06-02 08:08 2549

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares

SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and C...

2022-06-02 08:00 5657

First AI to Refine Medical Coding by Exploring Therapeutic Data

SAN FRANCISCO, June 1, 2022 /PRNewswire/ -- Medical AI start-up Aesop Technology announced a new partnership that made their new product,DxPrime , available in the Olive Library . DxPrime provides physicians and ...

2022-06-02 01:22 2516

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...

2022-06-01 21:00 2172

Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific

EAST RUTHERFORD, NJ, June 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a leading pr...

2022-06-01 18:00 2028

Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

* LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research * Safety profile is favourable and consistent with previous HMTM studies * TauRx will now pursue regulatory ...

2022-06-01 16:00 1720

AMGEN AND NSG BIOLABS ANNOUNCE GOLDEN TICKET TO BOOST SINGAPORE'S BIOTECH ECOSYSTEM

Amgen is the inaugural sponsor of the NSG Tomorrow Programme that aims to support innovation among biotech startups inSoutheast Asia SINGAPORE, June 1, 2022 /PRNewswire/ -- Amgen , a leading global biotechnology company, andNSG BioLabs , Singapore's l...

2022-06-01 10:00 2802

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

SAN FRANCISCO and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...

2022-06-01 08:00 2725

CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights

SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2021 full-year financial results a...

2022-06-01 00:35 5475

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 2764

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 1928

Nalagenetics obtains CE Mark for its pharmacogenomics software, Nala Clinical Decision Support™ Module- PGx Core

SINGAPORE, May 31, 2022 /PRNewswire/ -- Nalagenetics has just completed CE-marking for one of the reporting modules of its Clinical Decision Support (CDS) software. The registration enables its software to be marketed in Europe and support further approval inSoutheast Asia, where it aims to gain...

2022-05-31 21:09 2912

Rensselaer Polytechnic Institute and Icahn School of Medicine at Mount Sinai Announce Joint Center for Engineering and Precision Medicine

NEW YORK, May 31, 2022 /PRNewswire/ -- Rensselaer Polytechnic Institute and the Icahn School of Medicine atMount Sinai recently announced the creation of the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science ...

2022-05-31 21:00 2488

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinica...

2022-05-31 20:00 1499

Illuccix® Granted Transitional Pass-Through Payment Status

INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...

2022-05-31 19:00 1172

Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO

SHANGHAI, May 31, 2022 /PRNewswire/ -- Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led ...

2022-05-31 17:56 638

AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease

SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 st...

2022-05-31 11:30 1396
1 ... 135136137138139140141 ... 296